Double-digit revenue and EPS growth were driven by record sales of Dupixent, EYLEA HD, and Libtayo, with robust pipeline progress and strong cash flow supporting continued R&D and share repurchases. Key regulatory milestones are expected for cemdisiran and garetosmab, while EYLEA HD and Dupixent maintain strong momentum.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.